A detailed history of Edgestream Partners, L.P. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Edgestream Partners, L.P. holds 56,123 shares of BPMC stock, worth $5.08 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares
56,123
Previous 10,323 443.67%
Holding current value
$5.08 Million
Previous $1.11 Million 366.64%
% of portfolio
0.23%
Previous 0.05%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$84.1 - $120.5 $3.85 Million - $5.52 Million
45,800 Added 443.67%
56,123 $5.19 Million
Q2 2024

Aug 09, 2024

BUY
$85.18 - $108.78 $879,313 - $1.12 Million
10,323 New
10,323 $1.11 Million

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.